contact profile privacysearch log in


AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced the completion of enrollment and final treatment in its Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE). The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).
The SUO is excited to offer voiceover translations of the recordings from the 23rd Annual Meeting in Spanish and Portuguese. These videos will be available for purchase for non-members throughout 2023, and viewable on-demand. Members can view these videos by visiting the Past Meetings tab.
As an important person in the bladder cancer medical and research community, we want to make you aware of two prestigious awards from the Bladder Cancer Advocacy Network (BCAN) that you don’t want to miss.
This Is Your SUO
December 8, 2022
Last year, the Society of Urologic Oncology informed membership of our ongoing commitment to the growth and development of the organization. Over the last 12 months, we have worked with members to reevaluate our mission and develop strategies to advance the Society through a strategic plan designed to guide us for the next three to five years. We are excited to introduce this plan to our members, and look forward to the work ahead.
I would like to thank our fellows who worked hard this year and abstracted all the talks given at the SUO meeting at the AUA.
The American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO), released the 2022 clinical practice guideline for the management of clinically localized prostate cancer. The guideline has been endorsed by the Society of Urologic Oncology (SUO).
The Bladder Cancer Advocacy Network (BCAN) is pleased to announce that the Bladder Cancer Research Innovation Award is now open for Letter of Intent submissions until Wednesday, January 12, 2022.
In response to an RFI from NCI, the SUO submitted comments urging the lowering of the percent effort required for surgeon-scientists applying for K08 awards. The NCI responded to these and other organizations’ comments by making the following change to K08 applications submitted to NCI for due dates on or after the June 12th, 2021.
The Society of Urologic Oncology is pleased to provide valuable resources to advanced bladder cancer patients and caregivers.
The Society of Urologic Oncology sends condolences to the family and friends of Colonel David G. McLeod, MD, JD, MC, USA of the Walter Reed National Military Medical Center. Dr. McLeod passed away peacefully on Friday morning at his home in North Carolina.
A breakthrough therapy discovered during Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) Phase 2 and 3 trials was published by The Lancet Oncology.
Medical Breakthrough Tested in Phase 2 and 3 Trials from Society of Urologic Oncology Clinical Trials Consortium
Due to the rapidly escalating health concerns and developments related to the global coronavirus (COVID-19), the AUA 2020 Annual Meeting in Washington, DC has been cancelled. 
Thank you all for participating in the online vetting process for the SUO application for a Focused Practice Designation (FPD) in Urologic Oncology. The comments section provided much useful feedback regarding both support and areas of concern.
In 2018, the estimated number of new cases of urothelial bladder cancer (UC) in the United States was 81,000, with 17,240 estimated deaths. Comparable numbers from 2004 were approximately 64,000 and 12,000, respectively... Why has mortality from UC... remained unchanged for over 30 years?
This week, the Society of Urologic Oncology joined the American Urological Association, Bladder Cancer Advocacy Network, American Association of Clinical Urologists, LUGPA and Urology Care Foundation to express extreme concern about the shortage of TICE BCG and its effects on the care of patients with bladder cancer.
The American Joint Committee on Cancer (AJCC) has made available two important tools related to cancer staging on their website.
The role of genetic testing in prostate cancer is rapidly evolving. A substantial proportion of men with prostate cancer carry inherited genetic mutations in cancer risk genes, with estimates as high as 15% in men with metastatic castration resistant disease.
The American Board of Urology is beginning a new designation, called Focused Practice Designation (FPD). The purpose of the FPD is to recognize an area of sub-specialization within a specialty without the onerous need for the formal process of CAQ.
The Society of Urologic Oncology recently wrapped up another successful program at the 18th Annual Meeting. The Society saw its highest attendance yet with over 750 medical professionals present to learn about emerging medical techniques and engage in educational discussions. Meeting attendance is not the only thing on the rise, either, with membership in the Society nearing 1,000 members.
Durable responses in 35 percent of patients reported in Phase II data published in the Journal of Clinical Oncology
I am delighted on behalf of the editors and publisher of "Urologic Oncology: Seminars and Original Investigations" to share the exciting news of a dramatic increase in the journal's impact factor.
Three SUO members were honored at the SUO 2017 Annual Meeting at the AUA Saturday, May 13. 
The Society of Urologic Oncology (SUO) endorses the American Urological Association’s comments about the United States Preventative Services Task Force’s (USPSTF’s) updated statement on PSA screening for prostate cancer.
Congratulations to Dr. John L. Gore, University of Washington, on his impressive second-place performance at the Early Career Investigators Showcase at the recent AUA meeting in San Diego, for his work entitled, "Patient-Centered Design and Implementation of Survivorship Tools for Men with Prostate Cancer".
Introducing the SUO Career Center